BioMarin Licenses Subcutaneous Fabry Enzyme
On 29 October BioMarin signed an exclusive worldwide license, excluding Korea, for HM15421/GC1134A from GC Biopharma and Hanmi Pharm. The $70 million upfront is committed; up to $405 million in additional milestones and tiered…
